Galencia extends global reach with OM Pharma deal
Pharmaceutical manufacturer Galencia says its acquisition of Switzerland-based biotech group OM Pharma will bolster its international presence.
Galencia said the deal, which is scheduled to complete on October 31, will also expand its “pharma portfolio contributes to a better risk diversification.”
OM sells drugs in more than 90 countries around the world, with a focus on its four key products Broncho-Vaxo, Uro-Vaxom, Doxium and Dicynone which, Galencia believes, will boost its Vifor Pharma consumer healthcare unit.
The acquisition, financial terms of which are not being released, includes OM’s biotechnology production facility in Geneva that Galencia said will be an “important asset” for its manufacturing portfolio.
